Abstract:A member of the Janus kinase (JAK) family, Tyrosine Kinase 2 (TYK2), is crucial in mediating various cytokine-signaling pathways such as interleukin-23 (IL23), interleukin-12 (IL12) and type I Interferons (IFN) which contribute to autoimmune disorders (e.g., psoriasis, lupus, and inflammatory bowel disease). Thus, TYK2 represents an attractive target to develop small-molecule therapeutics for the treatment of cytokine-driven inflammatory diseases. Selective inhibition of TYK2 over other JAK isoforms is critical to achieve a favorable therapeutic index in the development of TYK2 inhibitors. However, designing small molecule inhibitors to target the adenosine triphosphate (ATP) binding site of TYK2 kinase has been challenging due to the substantial structural homology of the JAK family catalytic domains. Here, we employed an approach to target the JAK homology 2 (JH2) pseudokinase regulatory domain of the TYK2 protein. We developed a series of small-molecule TYK2 pseudokinase ligands, which suppress the TYK2 catalytic activity through allosteric regulation. The TYK2 pseudokinase-binding small molecules in this study simultaneously achieve high affinity-binding for the TYK2 JH2 domain while also affording significantly reduced affinity for the TYK2 JAK homology 1 (JH1) kinase domain. These TYK2 JH2 selective molecules, although possessing little effect on suppressing the catalytic activity of the isolated TYK2 JH1 catalytic domain in the kinase assays, can still significantly block the TYK2-mediated receptor-stimulated pathways by binding to the TYK2 JH2 domain and allosterically regulating the TYK2 JH1 kinase. These compounds are potent towards human T-cell lines and primary immune cells as well as in human whole-blood specimens. Moreover, TYK2 JH2-binding ligands exhibit remarkable selectivity of TYK2 over JAK isoforms not only biochemically but also in a panel of receptor-stimulated JAK1/JAK2/JAK3-driven cellular functional assays. In addition, the TYK2 JH2-targeting ligands also demonstrate high selectivity in a multi-kinase screening panel. The data in the current study underscores that the TYK2 JH2 pseudokinase is a promising therapeutic target for achieving a high degree of biological selectivity. Meanwhile, targeting the JH2 domain represents an appealing strategy for the development of clinically well-tolerated TYK2 inhibitors that would have superior efficacy and a favorable safety profile compared to the existing Janus kinase inhibitors against autoimmune diseases.

Catalytic Specificity of Protein-Tyrosine Kinases is Critical for Selective Signalling

Recognition and Specificity in Protein Tyrosine Kinase-Mediated Signalling

Switching of the Substrate Specificity of Protein Tyrosine Phosphatase N12 by Cyclin‐dependent Kinase 2 Phosphorylation Orchestrating 2 Oncogenic Pathways

The intrinsic substrate specificity of the human tyrosine kinome

The Structural Basis for Specificity in Protein-Tyrosine Kinase Signaling

Peptide And Protein Phosphorylation By Protein Tyrosine Kinase Csk: Insights Into Specificity And Mechanism

SH2 domains recognize specific phosphopeptide sequences.

EGF-receptor Specificity for Phosphotyrosine-Primed Substrates Provides Signal Integration with Src

High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

Functional selectivity of Receptor Tyrosine Kinases regulates distinct cellular outputs

An atlas of substrate specificities for the human serine/threonine kinome

Substrate Specificity Of Protein Tyrosine Phosphatases 1b, Rptp Alpha, Shp-1, And Shp-2

Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain

Catalytic Subunit A by Phosphorylating Tyrosine 330 of the Syk Inhibits the Activity of Protein Kinase Signal Transduction :

Surface Loops in a Single SH2 Domain Are Capable of Encoding the Spectrum of Specificity of the SH2 Family*

A dynamically coupled allosteric network underlies binding cooperativity in Src kinase

Phosphatidylinositol 3-kinase p85 SH2 domain specificity defined by direct phosphopeptide/SH2 domain binding

Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors